
• Reported GAAP EPS of $1.50 down -87.32% YoY • Reported revenue of $151.68M down -41.12% YoY
Bullish
Nutex Health achieved substantial FY2025 revenue and Adjusted EBITDA growth, supported by strong cash flow and balance sheet. Operational expansion for Nutex Health with increased patient visits also contributed.
Bearish
Nutex Health's Q4 revenue declined due to arbitration true-ups and high costs, alongside a significant increase in stock-based compensation. Q4 operating income and Adjusted EBITDA also saw sharp decreases.